Business / Finance

RSS

BioReliance inks non-exclusive license agreement with QTS for proprietary B-CLEAR technology

BioReliance, Sigma-Aldrich Corporation's biologics and early-development services business under SAFC Commercial, is pleased to announce a non-exclusive license agreement with Qualyst Transporter Solutions for its proprietary B-CLEAR technology.

21 Apr 2015

Kimberly-Clark's net sales decrease 4% to $4.7 billion in first quarter 2015

Kimberly-Clark Corporation today reported first quarter 2015 results and confirmed its previous guidance for full-year 2015 adjusted earnings per share.

21 Apr 2015

Tal Medical raises $14 million funding round from new and existing investors

Tal Medical, a clinical-stage medical device company developing a new treatment for depression and other psychiatric disorders, today announced a $14 million funding round from existing investor PureTech, a new institutional investor, and several prominent individual investors.

21 Apr 2015

Spirox closes $18.5 million Series B round of financing

Spirox Inc., a privately held medical device company, announced today the closing of an $18.5 million Series B round of financing led by Venrock and Aisling Capital. Existing investors Aperture Venture Partners, Correlation Ventures and Western Technology Investment also participated in the round.

20 Apr 2015

Paradigm to provide PCDx test to oncologists in TD2 networks

Paradigm and Translational Drug Development today announced a partnership under which Paradigm will provide their PCDx test to TD2's affiliated oncology provider networks.

20 Apr 2015

Contego Medical announces completion of $5.6 million Series B financing round

Contego Medical, the first and only provider of the Integrated Embolic Protection filter platform for angioplasty balloon and stent delivery catheters, announces the completion of a $5.6 million Series B financing round led by Hatteras Venture Partners, an early stage venture firm with a focus on medical devices, biopharmaceuticals, diagnostics and related opportunities in human medicine.

19 Apr 2015

Precision for Medicine announces acquisition of Precision Health Economics

Precision for Medicine, a specialized services company supporting next-generation approaches to drug development and commercialization, today announced the acquisition of Precision Health Economics.

16 Apr 2015

ChemRar, Lancet partner to develop and commercialize new medicines in Russia

ChemRar High Tech Center, the Russian pharmaceutical investment and R&D group, and Lancet, Russian Distribution Company, have announced collaboration for research, development and commercialization of new medicines in Russia with the intention to stimulate the innovative development of the Russian pharmaceutical industry.

16 Apr 2015

Significant progress for Epigem in SYMPHONY aflatoxin research

Epigem has developed, using microfluidics, a de-fatting device which is as efficient as a centrifuge and will reduce animal tests times from hours to minutes...

16 Apr 2015

India and Canada announce funding to improve maternal, child health in India

Grand Challenges Canada, funded by the Government of Canada, and the Grand Challenges India initiative of the Department of Biotechnology, Government of India, today announced an investment of $2.5 million (CAD) in five health innovations in India.

16 Apr 2015

Pivotal enters into sales, distribution agreement for BeneFishial family of products

Pivotal Therapeutics Inc., a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced today that it has entered into a Memorandum of Understanding with Korea Animal Medical Science Institute and its newly created affiliate for the exclusive sales and distribution of the BeneFishial family of products.

15 Apr 2015

SELLAS inks exclusive global collaboration, license agreement with TrojanTec

SELLAS Life Sciences Group, a Swiss based, development-stage biopharmaceutical company with its main focus in developing innovative products for the treatment of various indications in Oncology and the Central Nervous System, today announced that it has signed an exclusive global collaboration and license agreement with TrojanTec Ltd, a UK-based Discovery Research and Development Company affiliated with Imperial College London, UK, for the development, marketing and commercialization of the innovative and proprietary TR-1 cancer therapeutic technology and drug.

15 Apr 2015

Optibrium to integrate ChemAxon's Plexus with StarDrop software platform

Optibrium and ChemAxon, developers of software and cheminformatics solutions for drug discovery, today announced the results of a collaboration to integrate ChemAxon's Plexus with Optibrium's StarDrop software suite. The integration of these platforms further enables researchers to develop strategies for efficient, high quality compound library design.

15 Apr 2015

Warfarin and PT-INR testing: an interview with Paul Wright, CEO, Universal Biosensors

There are roughly 10 million people worldwide taking Warfarin, accounting for more than 200 million point of care (POC) PT-INR tests performed globally each year...

15 Apr 2015

Clyde Biosciences announces £2 million ‘Series A’ investment

Clyde Biosciences Ltd. has announced a £2 million ‘Series A’ investment led by Epidarex Capital, a leading international early-stage life science venture capital fund.

15 Apr 2015

Atlas Genetics signs diagnostic collaboration to explore new use of io system

Atlas Genetics Ltd, the ultra-rapid 'test and treat' molecular diagnostics company, today announces that it has entered into a collaboration with a major pharmaceutical company to develop a diagnostic test, expanding capabilities beyond infectious diseases.

15 Apr 2015

iCardiac launches industry-first full risk-sharing program for cardiac safety studies

iCardiac Technologies, a market and scientific leader in the conduct of cardiac safety assessments, announced today that it has launched the industry’s first full risk-sharing program for Thorough QT studies. Leveraging its innovative High Precision QT™ methodology for analyzing ECG waveforms, iCardiac’s program guarantees to sponsors that one of two desirable outcomes will be achieved.

14 Apr 2015

BioLight Life Sciences announces first IOPtiMate™ system sale in Hungary

BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced the first sale of the IOPtiMate™ system to a medical center located in Hungary.

14 Apr 2015

Clyde Biosciences, a leading drug toxicity testing company, closes Series A investment

Clyde Biosciences Ltd. (Clyde Biosciences) has announced a £2 million ‘Series A’ investment led by Epidarex Capital, a leading international early-stage life science venture capital fund. Scottish Enterprise’s investment arm, the Scottish Investment Bank, also participated in the round along with Glasgow University Holdings, Ltd.

14 Apr 2015

EarlySense signs partnership agreement with Mitsui

EarlySense Ltd., the market leader in contact-free monitoring solutions for the hospital and home, announced today it has signed a partnership agreement with Mitsui & Co., Ltd., one of the largest general trading companies in Japan, with revenues of 55.7 Billion USD and net income of 4,099 Million USD for the year ended March 31st, 2014.

14 Apr 2015